Special Reports

Achaogen
Agios Pharmaceuticals
Aileron
BioVex
Calistoga Pharmaceuticals

Clovis Oncology
Heptares Therapeutics
Ironwood
iZumi Bio
KaloBios

Pacific Biosciences
Portola Pharmaceuticals

Rexahn turns to deal-making as Phase II results loom Over the course of its eight-year history, Rexahn Pharmaceuticals' rep was been built primarily around its successful advancement of three key

by Maureen Martino and Calisha Myers Last month we brought you a list of the top 15 Pharma CEO Paychecks. And as promised, here's a look at the five highest-paid CEOs in the biotech industry. This

Bayhill turns to deal-making to fund its growth Mark Schwartz, PhD, doesn't like the idea of ranking Bayhill Therapeutics' two clinical programs. "We're working on a very innovative and new

A proven team gets $145M to take a familiar path Patrick Mahaffy thinks he has a pretty good business plan for his start-up biotech company. Gather an experienced biotech team, raise $145 million in

Tokai Pharmaceuticals Seth Harrison knows a thing or two about jump-starting a biotech company without busting the bank. As managing general partner at Apple Tree Partners, he's had the opportunity

VaxInnate breaks a new path in vaccine development The global alarm sounding over the outbreak of a new strain of H1N1 has once again highlighted just how inefficient the vaccine industry is. Using

Economic development programs have always played an important role in boosting the U.S. biotech industry. When a company has to invest years and millions of dollars just to get started, it needs

by Maureen Martino and Calisha Myers Welcome to to our second annual look at pharma CEO salaries. Every year, executive salaries cause a flap as industry watchers compare who makes what, who got a

Altor BioScience readies itself for Phase II To understand Altor BioScience's niche in the cancer field, you need to take a look at its lead program: ALT-801. Researchers took a cancer therapy, IL-2,